Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

NEXT STORY
Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program
PREV STORY
Global Facial Tissues Markets Report 2021-2030 Featuring Kimberly-Clark, Procter and Gamble, APP, Hengan, Vinda, C&S PAPER, Metsa Tissue, WEPA, Cascades and KP Tissue
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies

author_avatar
NASDAQ Market News

Europe Syringe Market Forecast to 2027 – COVID-19 Impact and Regional Analysis By Syringe Type, Application, Usability, and End User and Country

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical ...

author_avatar
NASDAQ Market News